Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can radiofrequency waves outperform acne gels?

NCT ID NCT07805655

Disease control Sponsor: Jeisys Medical Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This trial tests whether a radiofrequency device can reduce inflammatory acne lesions as effectively as a standard topical gel. About 60 adults with mild-to-moderate facial acne will be randomly assigned to receive either three radiofrequency sessions or daily application of a combination gel for 12 weeks. Researchers will compare changes in acne lesion counts, sebum production, and skin redness, and will also track safety and participant satisfaction.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sequential radiofrequency treatment using the Density Noir System (6.78 MHz) compared with a fixed-combination topical gel containing adapalene 0.1% and benzoyl peroxide 2.5%
What this could lead to
If radiofrequency works as well as or better than the standard gel, it could offer a new, non-drug option for people with mild-to-moderate acne who prefer to avoid daily topical medications.
What could go wrong
This is a small, early-stage trial with only 60 participants, so results may not apply to everyone. Radiofrequency can cause pain, redness, or swelling, and its effect on acne may not last beyond the follow-up period.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants aged 18-40 years. * Clinical diagnosis of mild-to-moderate inflammatory facial acne vulgaris, defined as Investigator Global Assessment (IGA) Grade 2 or 3. * Presence of 10-40 inflammatory facial lesions (papules and pustules). * Willing and able to comply with the study requirements, treatment schedule, and follow-up visits. * Able to understand the study procedures and provide written informed consent. Exclusion Criteria: * Severe acne, including nodulocystic acne. * Active skin infection, open wound, or other significant dermatologic condition in the treatment area that may interfere with study assessments or treatment. * Use of systemic isotretinoin within the protocol-specified period before enrollment. * Recent use of systemic or topical acne treatments that may interfere with evaluation of the study interventions. * Previous energy-based device treatment to the facial area within the protocol-specified period before enrollment. * Pregnancy or breastfeeding. * Presence of an implanted electronic device or other contraindication to radiofrequency treatment. * Known hypersensitivity or contraindication to adapalene, benzoyl peroxide, or other components of the comparator treatment. * Any medical condition or medication use that, in the investigator's judgment, may affect participant safety, study participation, or interpretation of study results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acne vulgaris are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acne Acne Vulgaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acne vulgaris

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Especialistas de la Piel y Cirugía, S.C.

    RECRUITING

    Nuevo León, Monterrey, 64060, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.